Represents the additional contribution amount to a collaboration.

No definition available.

Name:	abbv_AdditionalContributionToCollaboration
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the additional contribution amount to a collaboration by partner.

+ References

No definition available.

+ Details

Name:	abbv_AdditionalContributionToCollaborationByPartner
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the consideration from a counterparty for reacquired rights.

+ References

No definition available.

+ Details

Name:	abbv_ConsiderationFromCounterpartyForReacquiredRights
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents consideration to be received from counterparty for reacquired rights

+ References

No definition available.

+ Details

Name:	abbv_ConsiderationReceivableFromCounterpartyForReacquiredRights
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

This represents consideration received from counterparty for reacquired rights

+ References

No definition available.

+ Details

Name:	abbv_ConsiderationReceivedFromCounterpartyForReacquiredRights
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_PotentialPaymentsUnderAgreementCertainMilestones
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount owed for the achievement of certain milestone(s) under an agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_ResearchandDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationWrittenoffMilestonePayment
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The upfront amount owed under an agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_ResearchandDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationWrittenoffUpfrontPayment
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherOperatingIncomeExpenseNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow to acquire investments classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=abbv_CalicoLifeSciencesLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_TeneoOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_REGENXBIOIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_IMabBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_GenmabASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_ReataPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended			12 Months Ended
	Sep. 30, 2020	Oct. 31, 2019	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Cash outflows related to other acquisitions and investments						$ 1,377	$ 1,350	$ 1,135
Acquired in-process research and development						962	1,198	385
Other operating expense (income), net						432	0	(890)
Calico Life Sciences LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Additional contribution to collaboration by partner				$ 500
Calico Life Sciences LLC \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Additional contribution to collaboration				500
Other operating expense (income), net				500
TeneoOne \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments			$ 250			250
REGENXBIO Inc. \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments			1,400			1,400
I-Mab Biopharma \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments	$ 1,700
Genmab A/S \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments									$ 3,200
Reata Pharmaceuticals Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Other operating expense (income), net								(330)
Consideration received for acquired rights							250
Consideration receivable for acquired rights			80			80
Other individually insignificant arrangements \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired in-process research and development						192	248	$ 385
Other individually insignificant arrangements \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments			5,500			$ 5,500
In-process research and development \| TeneoOne \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired in-process research and development				$ 400
In-process research and development \| REGENXBIO Inc. \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment			$ 370
In-process research and development \| I-Mab Biopharma \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired in-process research and development					$ 200
Upfront payment	180
Milestone payment	$ 20
In-process research and development \| Genmab A/S \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired in-process research and development							$ 750
Other operating income \| Reata Pharmaceuticals Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Total consideration for acquired rights		$ 330